Related Experiment Video

Updated: Jul 12, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

The evolution of treatment strategies: aiming at the target

Phuong Dinh1, Christos Sotiriou, Martine J Piccart

  • 1Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B), 121 Blvd de Waterloo, 1000 Brussels, Belgium. phuong.dinh@bordet.be

Breast (Edinburgh, Scotland)
|September 4, 2007
PubMed

Insights

Adjuvant systemic therapy for early breast cancer is evolving from TNM classification to targeted treatments. Newer technologies like gene expression profiles promise more personalized therapies for better efficacy and reduced toxicity.

Area of Science:

  • Oncology
  • Translational Medicine
  • Genomics

Background:

  • Early breast cancer treatment historically relied on TNM staging.
  • The 2005 International St. Gallen Consensus shifted focus to identifying critical molecular targets.
  • Treatment selection now balances efficacy against toxicity, driven by receptor identification (estrogen, HER2).

Purpose of the Study:

  • To review the evolution of adjuvant systemic therapy selection in early breast cancer.
  • To highlight the transition from traditional risk assessment to targeted and personalized approaches.
  • To discuss the potential of emerging technologies in refining treatment strategies.

Main Methods:

  • Review of historical treatment selection criteria (TNM classification).
  • Analysis of the impact of molecular target identification (estrogen receptor, HER2).
  • Exploration of novel technologies: gene expression profiling, micrometastasis detection.

Main Results:

  • Significant success in adjuvant trials using targeted therapies (e.g., HER2-targeted agents).
  • Emerging technologies offer potential for further refinement of treatment strategies.
  • Identification of molecular subtypes, chemo-sensitivity/resistance, and metastatic potential.

Conclusions:

  • Adjuvant therapy for early breast cancer has significantly evolved towards personalized medicine.
  • Gene expression profiles and other novel technologies are key to tailoring treatment.
  • Future strategies aim to precisely match therapies to specific breast cancer subgroups for optimal outcomes.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Molecular Evolution of the Tre Recombinase12:02

Molecular Evolution of the Tre Recombinase

Published on: May 29, 2008

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...